Innovation Pharmaceuticals Inc (IPIX)

[Bad_Timing]

I think we can probably agree that everyone here that is paying attention knows that direct viral disruption is the primary MoA under investigation at the moment. So I don't get your comparison to drugs that only target replication. It sounds like you're making an argument that brilaciden is inferior because it's administered via IV. IMO that is not an obstacle because the target patient population has already been admitted to the hospital. A good argument could even be made that in hospitalized moderate to severe cases IV would be preferred.